Combined hepatocellular and cholangiocarcinoma (HCC-CC) is a rare primary liver cancer. It is constituted by neoplastic cells of both hepatocellular and cholangiocellular derivation. Different histology types of HCC-CC have been reported, hinting at heterogeneous carcinogenic pathways leading to the development of this cancer. Due to its rarity and complexity, mixed HCC-CC is a scantly investigated condition with unmet needs and unsatisfactory outcomes. Surgery remains the preferred treatment in resectable patients. The risk of recurrence, however, is high, especially in comparison with other primary liver cancers such as hepatocellular carcinoma. In unresectable or recurring patients, the therapeutic options are challenging due to the dual nature of the neoplastic cells. Consequently, the odds of survival of patients with HCC-CC remains poor. We analysed the literature systematically about the treatment of mixed HCC-CC, reviewing the main therapeutic options and their outcomes and analysing the most interesting developments in this topic with a focus on new potential therapeutic avenues.

Leoni S., Sansone V., De Lorenzo S., Ielasi L., Tovoli F., Renzulli M., et al. (2020). Treatment of combined hepatocellular and cholangiocarcinoma. CANCERS, 12(4), 794-809 [10.3390/cancers12040794].

Treatment of combined hepatocellular and cholangiocarcinoma

Leoni S.;Sansone V.;De Lorenzo S.;Ielasi L.;Tovoli F.;Renzulli M.;Golfieri R.;Spinelli D.;Piscaglia F.
2020

Abstract

Combined hepatocellular and cholangiocarcinoma (HCC-CC) is a rare primary liver cancer. It is constituted by neoplastic cells of both hepatocellular and cholangiocellular derivation. Different histology types of HCC-CC have been reported, hinting at heterogeneous carcinogenic pathways leading to the development of this cancer. Due to its rarity and complexity, mixed HCC-CC is a scantly investigated condition with unmet needs and unsatisfactory outcomes. Surgery remains the preferred treatment in resectable patients. The risk of recurrence, however, is high, especially in comparison with other primary liver cancers such as hepatocellular carcinoma. In unresectable or recurring patients, the therapeutic options are challenging due to the dual nature of the neoplastic cells. Consequently, the odds of survival of patients with HCC-CC remains poor. We analysed the literature systematically about the treatment of mixed HCC-CC, reviewing the main therapeutic options and their outcomes and analysing the most interesting developments in this topic with a focus on new potential therapeutic avenues.
2020
Leoni S., Sansone V., De Lorenzo S., Ielasi L., Tovoli F., Renzulli M., et al. (2020). Treatment of combined hepatocellular and cholangiocarcinoma. CANCERS, 12(4), 794-809 [10.3390/cancers12040794].
Leoni S.; Sansone V.; De Lorenzo S.; Ielasi L.; Tovoli F.; Renzulli M.; Golfieri R.; Spinelli D.; Piscaglia F.
File in questo prodotto:
File Dimensione Formato  
cancers-12-00794-v2.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 276.45 kB
Formato Adobe PDF
276.45 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/767929
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 32
social impact